GLSI | Greenwich LifeSciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.86 - 12.34
52 Week Range	10.52 - 21.44
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	14,192
Average Volume	33,538
Shares Outstanding	13,144,700
Market Cap	162,074,151
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-25

Valuation
Profitability
Growth
Health
P/E Ratio	-15.22
Forward P/E Ratio	N/A
EPS	-0.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	GLSI

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

GLSI's peers: EYEN, RVPH, IMMP, AVXL, VRPX, ACXP, MNOV, NXTC, ENTX, XFOR, TERN, DAWN, PDSB, INZY, AMLX, ABOS, GNPX

*Chart delayed

Analyzing fundamentals for GLSI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see GLSI Fundamentals page.

Watching at GLSI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GLSI Technicals page.